Ernexa Reports Positive ERNA-101 Safety Data Ahead Of Q4 IND

September 30, 2026 — 09:12 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Wednesday, Ernexa Therapeutics (ERNA) reported positive results from three IND-enabling safety studies of ERNA-101, its investigational iMSC therapy for advanced cancers.

ERNA-101 is an engineered cell therapy designed to deliver an IL-7/IL-15 fusion cytokine to tumors and is initially being developed for platinum-resistant ovarian cancer.

Across repeat-dose toxicology, tumorigenicity and biodistribution studies, ERNA-101 showed no treatment-related adverse findings, no teratoma formation through six months and no significant signal in non-tumor tissues.

Ernexa said its core safety studies are complete, GMP manufacturing is underway, and it remains on track to submit an IND to the FDA in the fourth quarter of 2026.

ERNA shares closed on Tuesday at $3.16, down 8.93%.

In the Premarket trading, shares are up 8.86% at $3.44.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Ernexa Reports Positive ERNA-101 Safety Data Ahead Of Q4 IND

Tags

Latest Articles